Dr. Andrew V. Schally, a Nobel Laureate in Medicine, is continuing his work on the development and preclinical evaluation of peptide analogs with antitumor activity. This program is aimed at providing a theoretical, preclinical, and mechanistic basis for planned clinical trials with these peptide analogs in various cancers, including prostatic, pancreatic, gastric, colorectal, malignant brain tumors, small cell lung cancer and non-small cell lung cancer, bladder cancer, renal and thyroid cancer, osteosarcomas, melanomas, hepatocellular carcinoma, and lymphomas. Overall, this program has the potential to make a significant impact on the improvements of therapeutic methods and the delivery of care to the patients afflicted with various cancers. Updated July 2017
Andrew Schally
Professor of Pathology, University of Miami
Born in: Poland
![Andrew Schally](https://media.carnegie.org/filer_public_thumbnails/filer_public/34/37/3437acdd-5f60-44ea-86f1-22fc59ea1b2c/dr_andrew_v_schally-portrait.jpeg__288x288_q85_crop_subsampling-2_upscale.jpg)
More 2017 Great Immigrants
Thai LeePresident and CEO, SHI International Corporation
Sir J. Fraser StoddartBoard of Trustees Professor of Chemistry, Northwestern University
Norma TorresRepresentative, 35th District of California, United States House of Representatives
Chinelo OkparantaAuthor
Get the Carnegie Reporter and our best articles delivered to your inbox.